J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six weeks, with benefit remaining …
Post
-
-
The advantages of a platform approach in clinical trial data management
Clinical trials are producing more data than ever before, drawing from vast and diverse datasets that must be cleaned and …
-
Ocugen sets sights on Phase III after GA gene therapy win
Ocugen has posted positive results for its lead investigational gene therapy, OCU410, in geographic atrophy (GA) secondary to dry age-related …
-
QPS adopts Oracle Argus to advance safety in clinical trials
US-based contract research organisation QPS Holdings (QPS) has implemented a new clinical trial pharmacovigilance system, Oracle Argus, to advance safety …
-
Axsome begins Phase III AXS-14 FORWARD trial for fibromyalgia management
Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 (esreboxetine) for the management of fibromyalgia, with the first …
-
JPM26: Leo Pharma’s growth strategy puts a spotlight on rare dermatology diseases
Leo Pharma’s bold commitment to be a strong player in the dermatological space was made clear at the J.P Morgan …
-
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death
Intellia Therapeutics is confident in the safety profile of its gene therapies after revealing that a man's death in a …
-
JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in …
-
FDA and EMA release collaborative AI framework for drug development
In a bid to optimise the use of AI in drug development, US and European regulators have banded together to …
-
New study finds stroke associated with poor glycemic control in diabetics
Diabetes mellitus is a common disease that affects how the body uses blood sugar and can lead to excess glucose …
-
From Fragmented to Unified: How Flex Databases Is Rewiring Clinical Operations for the AI Era
With pressure mounting to shorten timelines and tighten oversight, Flex Databases is betting on a single, configurable eClinical platform to …
-
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
ImmunityBio’s immunotherapy drug Anktiva (nogapendekin alfa inbakicept) has shown success in combination with a checkpoint inhibitor in two non-small cell …
-
Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer
Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in …
-
JPM26: Sanofi’s COAST 1 clinical trials exhibit positive results, with researchers optimistic for COAST 2 results for amlitelimab
Sanofi is excited for 2026. At the JP Morgan Healthcare conference, several upcoming catalyst events were highlighted, including high-profile read-outs, …
-
JPM26: 2025 a “breakout year” for rare disease biotechs
Developers in rare disease emphasise cashflow and R&D expansion as evidence of their transition from emerging biotechs to established companies …
